| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Expert-backed, patient-focused testing
Mayo Clinic Laboratories’ testing is developed and validated in partnership with the Molecular Technologies Laboratory, Clinical Mass Spectrometry Laboratory, Center for Individualized Medicine (CIM), and the Schulze Center for Novel Therapeutics at Mayo Clinic. Our testing offers:
Excellence in analytical and clinical quality: Tests include only actionable genes with a high level of clinical evidence. We include more alleles per gene (up to two times as many) as our competitors. Our tests are designed to include clinically significant variants across diverse populations to ensure testing appropriateness for patients around the world.
End-to-end testing: Access to both PGx testing and TDM testing for a comprehensive list of antidepressants in one laboratory.
Interpretive support: We offer consultations with Mayo Clinic physicians, laboratory directors, PGx pharmacists, genetic counselors, and other toxicology experts to help guide test ordering and interpretation. In addition, our reports include medication recommendations categorized by drug class and reference sources of information to ensure easy interpretation.
Unparalleled breadth of vision: We support our PGx clients throughout their PGx journey through access to Mayo Clinic’s PGx certificate program, interpretative support, and clinical decision support.
The right medication for the right patient at the right dose
Indications for precision therapeutics testing may include:
For optimal outcomes, both PGx and therapeutic drug monitoring must be interpreted in the full context of a patient’s clinical picture, including demographic and clinical characteristics.
“Both pharmacogenomics and therapeutic drug monitoring can help maximize efficacy while minimizing toxicity for antidepressant therapy.”
Paul Jannetto, Ph.D., co-director of the Clinical and Forensic Toxicology Laboratory
The latest
Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for safer cancer treatment.
Recognizing the powerful role genes can play in diagnosing illness and guiding treatment, the Division of Laboratory Genetics and Genomics at Mayo Clinic spearheaded a testing expansion, implementing and upgrading more than 60 advanced sequencing and biochemical assays in 2023 and planning for even more this year.
Ann Moyer, M.D., Ph.D., and Paul Jannetto, Ph.D., explain how precision therapeutics can improve treatment for patients with major depressive disorder. The optimal antidepressant medication and dose vary among individuals. Pharmacogenomic testing and therapeutic drug monitoring can guide clinicians to the most-effective treatment for each patient.
Ann Moyer, M.D., Ph.D., explains Mayo Clinic Labs’ new focused pharmacogenomics panel, a real-time, PCR-based testing approach that assesses 10 genes known for their drug-gene associations, to provide guidance on medication selection for patients across a variety of specialities.